{"disease":{"id":"pemphigoid","name":"pemphigoid"},"drugs":{"marketed":[{"drug_id":"azathioprine","indication_name":"Bullous pemphigoid","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imuran","generic_name":"AZATHIOPRINE","company_name":"Legacy Pharma","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Purine Antimetabolite [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe bullous pemphigoid","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe mucous membrane pemphigoid","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe bullous pemphigoid in infants and children","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe mucous membrane pemphigoid in infants and children","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05954416","title":"FARD (RaDiCo Cohort) (RaDiCo-FARD)","phase":"","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT02313870","title":"Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":322,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT06213909","title":"Retrospective Study of the Effects of Sub-pathologic Phenotypes of BP on Clinical Management and Prognosis","phase":"","overall_status":"UNKNOWN","enrollment_count":318,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT07210554","title":"Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Chengdu Kangnuoxing Biopharma,Inc.","has_results":false},{"nct_id":"NCT03320798","title":"Impact of Neurological Diseases on the Prognosis of Bullous Pemphigoid: A Retrospective Study of 178 Patients","phase":"","overall_status":"COMPLETED","enrollment_count":178,"lead_sponsor_name":"CHU de Reims","has_results":false},{"nct_id":"NCT05366127","title":"Validation of a Simplified Severity Score (Investigator Global Assessment: IGA) in Bullous Pemphigoid","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":150,"lead_sponsor_name":"University Hospital, Rouen","has_results":false},{"nct_id":"NCT02837965","title":"Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid","phase":"","overall_status":"COMPLETED","enrollment_count":149,"lead_sponsor_name":"CHU de Reims","has_results":false},{"nct_id":"NCT05649579","title":"Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid","phase":"","overall_status":"COMPLETED","enrollment_count":146,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT06371417","title":"Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":144,"lead_sponsor_name":"Chugai Pharmaceutical","has_results":false},{"nct_id":"NCT06723106","title":"Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)","phase":"PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":144,"lead_sponsor_name":"Chugai Pharmaceutical","has_results":false},{"nct_id":"NCT06479018","title":"Deciphering IL-17-dependant Inflammatory Response in Bullous Pemphigoid","phase":"NA","overall_status":"RECRUITING","enrollment_count":140,"lead_sponsor_name":"CHU de Reims","has_results":false},{"nct_id":"NCT02823067","title":"Pruritus and Pemphigoid in Nursing Home Patients","phase":"","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"M.F. Jonkman","has_results":false},{"nct_id":"NCT02502903","title":"Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"Bioverativ, a Sanofi company","has_results":false},{"nct_id":"NCT07188402","title":"Prevalence of Sleep Disturbances in Bullous Pemphigoid Patients.","phase":"","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"University Hospital, Rouen","has_results":false},{"nct_id":"NCT05284929","title":"Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population","phase":"","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Sechenov University","has_results":false},{"nct_id":"NCT06561256","title":"JAK Inhibitors' Efficacy in Bullous Pemphigoid","phase":"","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Chao Ji","has_results":false},{"nct_id":"NCT04469582","title":"The Association of Bullous Pemphigoid With Dipeptidyl-peptidase 4 Inhibitors","phase":"","overall_status":"UNKNOWN","enrollment_count":113,"lead_sponsor_name":"University of Athens","has_results":false},{"nct_id":"NCT04206553","title":"A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":106,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT05267600","title":"A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":98,"lead_sponsor_name":"argenx","has_results":true},{"nct_id":"NCT04641884","title":"Bullous Pemphigoid Induced by antiPD-1/PDL-1 Therapy","phase":"","overall_status":"UNKNOWN","enrollment_count":85,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT04612790","title":"A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":67,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT05681481","title":"A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":64,"lead_sponsor_name":"argenx","has_results":true},{"nct_id":"NCT03272958","title":"Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid","phase":"","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT05984381","title":"Efficacy and Safety of add-on Dapsone Versus add-on Methotrexate in Patients With Bullous Pemphigoid","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"All India Institute of Medical Sciences, Bhubaneswar","has_results":false},{"nct_id":"NCT06148090","title":"Screening for Adrenal Insufficiency During Dermocorticoid Reduction in Bullous Pemphigoid (BP)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT06291350","title":"Peridontal and Intestinal Microbiota in Patients With Gingival Scarring Pemphigoid","phase":"","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT01705795","title":"Anti-IL-5 Therapy in Bullous Pemphigoid (BP)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Insel Gruppe AG, University Hospital Bern","has_results":false},{"nct_id":"NCT05594472","title":"Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT02360202","title":"Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"University Hospital, Rouen","has_results":false},{"nct_id":"NCT04540133","title":"Dexamethasone Solution and Dexamethasone in Mucolox™","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT04555681","title":"Study of the Periodontal Microbiota in Gingival Cicatricial Pemphigoid Patients. Bicentric Pilot Study.","phase":"","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT03856840","title":"Cytokines in Blister Fluids of Bullous Pemphigoid (BP)","phase":"","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Mahmut Can Koska","has_results":false},{"nct_id":"NCT04728854","title":"Telederm and Bullous Pemphigoid","phase":"","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT05520086","title":"Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis.","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","has_results":false},{"nct_id":"NCT04117932","title":"Efficacy and Safety of Ustekinumab in Bullous Pemphigoid","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"CHU de Reims","has_results":false},{"nct_id":"NCT04465292","title":"The Effects of Tildrakizumab in Treatment of Bullous Pemphigoid","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":16,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT04563923","title":"Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT01559155","title":"Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid","phase":"","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nīmes","has_results":false},{"nct_id":"NCT02226146","title":"Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04744623","title":"Clinical Evaluation of New Treatment Strategy of Mucous Membrane Pemphigoid Using Large Dose of Prednisolone Plus Intra-lesional of Triamcinolone Acetonide Followed by Combination of Mycophenolate Mofetil, Dapsone and Low Dose Prednisolone","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"Tanta University","has_results":false},{"nct_id":"NCT03286582","title":"A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"TWi Biotechnology, Inc.","has_results":false},{"nct_id":"NCT04035733","title":"rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"AKARI Therapeutics","has_results":false},{"nct_id":"NCT06926478","title":"Subconjunctival Humira for Boston Keratoprosthesis","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":8,"lead_sponsor_name":"Massachusetts Eye and Ear Infirmary","has_results":false},{"nct_id":"NCT04499235","title":"A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Alkahest, Inc.","has_results":true},{"nct_id":"NCT01571895","title":"Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Dompé Farmaceutici S.p.A","has_results":false},{"nct_id":"NCT03099538","title":"Ixekizumab in the Treatment of Bullous Pemphigoid","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT05263505","title":"Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT05061771","title":"Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)","phase":"PHASE3","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"AKARI Therapeutics","has_results":false},{"nct_id":"NCT05906706","title":"Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false}],"total":49},"guidelines":[],"source":"Drug Landscape verified database"}